TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20

TD Cowen analyst Stacy Ku maintains $BioCryst Pharmaceuticals(BCRX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 22.7% and

moomoo NewsJun 20 07:32 ET · Ratings

BioCryst Pharmaceuticals(BCRX.US) Director Sells US$28,134 in Common Stock

$BioCryst Pharmaceuticals(BCRX.US)$ Director SANDERS MACHELLE sold 4,689 shares of common stock on Jun 17, 2024 at an average price of $6 for a total value of $28,134.Source: Announcement What is stat

moomoo NewsJun 17 17:17 ET

BioCryst Pharmaceuticals(BCRX.US) Director Sells US$40,924.78 in Common Stock

$BioCryst Pharmaceuticals(BCRX.US)$ Director HEGGIE THERESA sold 6,698 shares of common stock on Jun 14, 2024 at an average price of $6.11 for a total value of $40,924.78.Source: Announcement What is

moomoo NewsJun 14 17:09 ET

Most Shareholders Will Probably Agree With BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) CEO Compensation

Yahoo FinanceJun 6 06:04 ET

Press Release: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced t

Dow JonesJun 4 07:00 ET

BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients

BioCryst Pharmaceuticals (BCRX) said Sunday an analysis showed that six patients with hereditary angioedema experienced a reduction in monthly attacks while taking oral, once-daily Orladeyo. BioCryst

MT NewswiresJun 3 03:46 ET